EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin

Colin J Vize, Stella K Kim, Tim Matthews, Marian Macsai, Ryan Merrell, Sigmund Hsu, Madan Gopal Kundu, Jennifer Yoon, Emma Kennedy, Madhavi Pai, Earle Bain, Andrew B Lassman und 1 weitere

Ophthalmic Research · 2023

DOI: 10.1159/000531142 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Ophthalmic Research, 2023. Verfasst von Colin J Vize und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Hull University Teaching Hospitals NHS Trust, Hull, UK. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Understanding New Interventions with GBM ThErapy (UNITE) study was designed to assess the effect of prophylaxis for ocular side effects (OSEs) in patients with glioblastoma receiving the antibody-drug conjugate (ADC) depatuxizumab mafodotin. UNITE (NCT03419403) was a phase 3b, open-label, randomized, exploratory study performed at 18 research sites in 5 countries.

Methods

The study enrolled adult patients with epidermal growth factor receptor-amplified, histologically confirmed, newly diagnosed supratentorial glioblastoma or grade IV gliosarcoma, and a Karnofsky Performance Status ≥70, receiving depatuxizumab mafodotin. All patients were administered depatuxizumab mafodotin during concurrent radiotherapy and temozolomide and with adjuvant temozolomide. Ninety patients were to be randomized (1:1:1) to OSE prophylactic treatments with each depatuxizumab mafodotin infusion: (a) standard steroid eye drops, (b) standard steroid eye drops plus vasoconstrictor eye drops and cold compress, or (c) enhanced steroids plus vasoconstrictor eye drops and cold compress. A Corneal Epitheliopathy Adverse Event (CEAE) scale was devised to capture symptoms, grade OSEs (scale of 0–5), and inform ADC dose modifications. The primary endpoint was the frequency of a required change in OSE management due to inadequate control of OSEs, defined as decline from baseline in visual acuity (using logarithm of the minimum angle of resolution [LogMAR] scale) or a Grade ≥3 CEAE event, in the worst eye in the first 8 weeks of treatment; unless otherwise specified, the treatment period refers to both the chemoradiation and adjuvant phases.

Results

The UNITE study was stopped early after interim analysis of separate phase III trial showed no difference in survival from depatuxizumab mafodotin. Forty patients were randomized (38 received depatuxizumab mafodotin). Overall, 23 patients experienced inadequate control of OSEs that required change in OSE management within 8 weeks of treatment, with 21 (70.0%) experiencing ≥+0.3 change on LogMAR scale in baseline-adjusted visual acuity and 12 reporting a grade ≥3 CEAE. There were no definitive differences among prophylactic treatments.

Conclusions

The premature cessation of the study precludes definitive conclusions regarding the OSE prophylaxis strategies. No new clinically significant safety findings were noted. Despite these limitations, this study highlights the need for novel assessment tools to better understand and mitigate OSEs associated with ADCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAdultHumansErbB ReceptorsOphthalmic SolutionsSteroidsTemozolomideVasoconstrictor AgentsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Antibody-drug conjugateCorneal epitheliopathyDepatuxizumab mafodotinEpidermal growth factor receptorOcular side effect

Substanzen

ErbB ReceptorsOphthalmic SolutionsSteroidsTemozolomideVasoconstrictor Agentsdepatuxizumab mafodotinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, Hull University Teaching Hospitals NHS Trust, Hull, UK.
  • Department of Ophthalmology and Visual Science, University of Texas McGovern Medical School, Houston, Texas, USA.
  • Birmingham Neuro-Ophthalmology Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Northshore University Health System, Glenview, Illinois, USA.
  • NorthShore University Health System, Evanston, Illinois, USA.
  • The Vivian L. Smith Department of Neurosurgery, University of Texas McGovern Medical School, Houston, Texas, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Vize, C. J., Kim, S. K., Matthews, T., Macsai, M., Merrell, R., Hsu, S., Kundu, M. G., Yoon, J., Kennedy, E., Pai, M., Bain, E., Lassman, A. B., & Moazami, G. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research. https://doi.org/10.1159/000531142

Vancouver

Vize CJ, Kim SK, Matthews T, Macsai M, Merrell R, Hsu S, et al. A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research. 2023. doi:10.1159/000531142

BibTeX
@article{Vize2023,
  author = {Vize, Colin J and Kim, Stella K and Matthews, Tim and Macsai, Marian and Merrell, Ryan and Hsu, Sigmund and Kundu, Madan Gopal and Yoon, Jennifer and Kennedy, Emma and Pai, Madhavi and Bain, Earle and Lassman, Andrew B and Moazami, Golnaz},
  title = {A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin},
  journal = {Ophthalmic Research},
  year = {2023},
  doi = {10.1159/000531142}
}
Kostenlos starten →